IOBT insider transaction filings
IO Biotech, Inc. — 30 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-06-06. Screen IOBT transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for IOBT between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — IO Biotech, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-06-06 | 4 | Hunter Heidi — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Elling Christian E — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Hirth Peter — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Collins Helen Louise — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Glaub Kathleen Sereda — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Smith David V — Director | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Hunter Heidi — Director | Purchase (P): 15,000 @ $1.39 | EDGAR |
| 2025-04-04 | 4 | Zocca Mai-Britt — Chief Executive Officer, Director | Grant/award (A): 580,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Sullivan Amy — Chief Financial Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Burkavage Brian — Chief Accounting Officer | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Ahmad Qasim Iftikhar — Chief Medical Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Smith Devin Whittemore — General Counsel | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2024-12-26 | 4 | Ahmad Qasim Iftikhar — Chief Medical Officer | Purchase (P): 31,350 @ $0.85 | EDGAR |
| 2024-12-23 | 4 | Zocca Mai-Britt — Chief Executive Officer, Director | Purchase (P): 12,500 @ $0.81 | EDGAR |
| 2024-12-23 | 4 | Sullivan Amy — Chief Financial Officer | Purchase (P): 10,250 @ $0.83 | EDGAR |
| 2024-12-23 | 4 | Smith Devin Whittemore — General Counsel | Purchase (P): 12,000 @ $0.81 | EDGAR |
| 2024-07-26 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 51,522 @ $1.33 · Sale (S): 23,478 @ $1.31 | EDGAR |
| 2024-06-07 | 4 | Hunter Heidi — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Elling Christian E — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Hirth Peter — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Collins Helen Louise — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Glaub Kathleen Sereda — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Smith David V — Director | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-05-14 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 658,809 @ $1.22 | EDGAR |
| 2024-03-18 | 4 | Zocca Mai-Britt — Chief Executive Officer, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Sullivan Amy — Chief Financial Officer | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Burkavage Brian — Chief Accounting Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Ahmad Qasim Iftikhar — Chief Medical Officer | Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | Smith Devin Whittemore — General Counsel | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Novo Holdings A/S — 10% owner | Sale (S): 658,809 @ $1.50 | EDGAR |
Recent 8-K events — IO Biotech, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-03-31 | 8-K | 1.03 — Bankruptcy or Receivership 2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2026-02-13 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-30 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2025-11-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-29 | 8-K | ? 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IOBT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →